UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
暂无分享，去创建一个
J. Lemonnier | M. Campone | J. Canon | J. Pierga | V. D’Hondt | N. Dohollou | F. Dalenc | S. Delaloge | E. Brain | M. Debled | J. Ferrero | A. Gonçalves | D. Serin | A. Hardy-Bessard | C. Lévy | I. Desmoulins | H. Roché | H. Orfeuvre | L. Roca | M. Rios | G. Piot | F. Le Du | V. D'Hondt